OCT 01, 2015 12:00 PM PDT

Keynote Presentation (during an actual infusion!): Patient #1 - Pioneering Immunotherapy and Finding The Best, Right Treatment for Stage IV Melanoma

2 18 1110

  • Patient, Survivor, Advocate, and Author of the "Patient #1" blog
      T.J. Sharpe is sharing his fight against Stage 4 Melanoma in his weekly Patient #1 blog on www.Philly.com/Patient1. A South Jersey native and Bishop Eustace and Carnegie Mellon University graduate, he currently lives in Fort Lauderdale, FL with his wife Jennifer and children Josie and Tommy. He was Patient #1 in a clinical trial at Moffitt Cancer Center in Tampa as the first person worldwide to use this sequence of treatments to fight melanoma, and is currently in a second clinical trial at Holy Cross Hospital in Fort Lauderdale receiving Merck's anti-PD-1 drug pembrolizumab


    Stage IV melanoma carried a 24 month life expectancy three short years ago. That is what T.J. Sharpe’s first oncologist told him he was facing, after a visit to the ER for a fever turned into a metastatic melanoma diagnosis. His quest to overcome these long odds and beat cancer has taken him through two clinical trials, four immunotherapies, and six surgeries – all while sharing the highs and lows of cancer treatment on www.Philly.com. Fortunately, those three years have seen a great advance in melanoma treatments, one Mr. Sharpe has witnessed first-hand and shared with the world through his blog, advocacy speaking, and participation in conferences for cancer, biotechnology, and clinical trials. Being a husband and father (second child Tommy was born a mere four weeks before the diagnosis), his story combines the medicinal side of the current immunotherapy treatments being presented at the Labroots Cancer Research and Oncology event, alongside how these treatments affect everyday life. It also gives medical professionals, researchers, caretakers, and other cancer patients insight into getting the best, right care and how to overcome the avalanche of information and decisions that a cancer diagnosis brings. While he is sharing his patient perspective, T.J. will receive his 42nd dose of pembrolizumab, as part of the second clinical trial.

    Show Resources
    Loading Comments...